Cargando…

Comparative Efficacy of Lobeglitazone Versus Pioglitazone on Albuminuria in Patients with Type 2 Diabetes Mellitus

INTRODUCTION: The aim of this analysis was to evaluate the efficacy of lobeglitazone on albuminuria at 24 weeks of follow-up in patients with type 2 diabetes mellitus (T2DM) compared with pioglitazone using data from a randomized, double-blinded phase III trial. METHODS: In the phase III trial, pati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Kyung-Soo, Hong, Sangmo, Ahn, Hong-Yup, Park, Cheol-Young
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7843821/ https://www.ncbi.nlm.nih.gov/pubmed/33099742 http://dx.doi.org/10.1007/s13300-020-00948-1

Ejemplares similares

Lobeglitazone: A Novel Thiazolidinedione for the Management of Type 2 Diabetes Mellitus
por: Bae, Jaehyun, et al.
Publicado: (2021)

A Real-World Study of Long-Term Safety and Efficacy of Lobeglitazone in Korean Patients with Type 2 Diabetes Mellitus
por: Kim, Bo-Yeon, et al.
Publicado: (2022)

Structures of PPARγ complexed with lobeglitazone and pioglitazone reveal key determinants for the recognition of antidiabetic drugs
por: Lee, Min A, et al.
Publicado: (2017)

Structural Basis for the Enhanced Anti-Diabetic Efficacy of Lobeglitazone on PPARγ
por: Jang, Jun Young, et al.
Publicado: (2018)

Metabolic Dysfunction-Associated Fatty Liver Disease and Mortality: A Population-Based Cohort Study
por: Kim, Kyung-Soo, et al.
Publicado: (2023)

The Clinical Characteristics of Gestational Diabetes Mellitus in Korea: A National Health Information Database Study
por: Kim, Kyung-Soo, et al.
Publicado: (2021)

Effects of Lobeglitazone, a Novel Thiazolidinedione, on Bone Mineral Density in Patients with Type 2 Diabetes Mellitus over 52 Weeks
por: Lim, Soo, et al.
Publicado: (2017)

Evaluation of pharmacokinetic interactions between lobeglitazone, empagliflozin, and metformin in healthy subjects
por: Kim, Heeyoung, et al.
Publicado: (2023)

Efficacy and Safety of Lobeglitazone Monotherapy in Patients with Type 2 Diabetes Mellitus over 24-Weeks: A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo Controlled Trial
por: Kim, Sin Gon, et al.
Publicado: (2014)

Association Between Hearing Impairment and Albuminuria With or Without Diabetes Mellitus
por: Jung, Da Jung, et al.
Publicado: (2017)

Diabetes Mellitus and Albuminuria
Publicado: (1882)

Effect of pioglitazone on serum concentrations of osteoprotegerin in patients with type 2 diabetes mellitus
por: Park, Jong Suk, et al.
Publicado: (2011)

Effect of Dapagliflozin in Combination with Lobeglitazone and Metformin in Korean Patients with Type 2 Diabetes in Real-World Clinical Practice
por: Seo, Da Hea, et al.
Publicado: (2022)

Lobeglitazone inhibits LPS-induced NLRP3 inflammasome activation and inflammation in the liver
por: Seo, Hye-Young, et al.
Publicado: (2023)

Lobeglitazone and pioglitazone as add‐ons to metformin for patients with type 2 diabetes: a 24‐week, multicentre, randomized, double‐blind, parallel‐group, active‐controlled, phase III clinical trial with a 28‐week extension
por: Jin, S.‐M., et al.
Publicado: (2015)

Therapeutic efficacy and safety of initial triple combination of metformin, sitagliptin, and lobeglitazone in drug-naïve patients with type 2 diabetes: initial triple study
por: Lim, Soo, et al.
Publicado: (2020)

Comparative Study of Ex Vivo Antiplatelet Activity of Aspirin and Cilostazol in Patients with Diabetes and High Risk of Cardiovascular Disease
por: Hong, Sangmo, et al.
Publicado: (2022)

Effects of Lobeglitazone, a New Thiazolidinedione, on Osteoblastogenesis and Bone Mineral Density in Mice
por: Kim, Kyoung Min, et al.
Publicado: (2017)

Comparison of the Usefulness of the Updated Homeostasis Model Assessment (HOMA2) with the Original HOMA1 in the Prediction of Type 2 Diabetes Mellitus in Koreans
por: Song, Young Seok, et al.
Publicado: (2016)

Effects of lobeglitazone on insulin resistance and hepatic steatosis in high-fat diet-fed mice
por: Choi, Bong-Hoi, et al.
Publicado: (2018)

Treatment with Lobeglitazone Attenuates Hepatic Steatosis in Diet-Induced Obese Mice
por: Choung, Sorim, et al.
Publicado: (2018)

Efficacy and safety of teneligliptin in combination with pioglitazone in Japanese patients with type 2 diabetes mellitus
por: Kadowaki, Takashi, et al.
Publicado: (2013)

Lobeglitazone Attenuates Airway Inflammation and Mucus Hypersecretion in a Murine Model of Ovalbumin-Induced Asthma
por: Shin, Na-Rae, et al.
Publicado: (2018)

Assessing the Validity of the Criteria for the Extreme Risk Category of Atherosclerotic Cardiovascular Disease: A Nationwide Population-Based Study
por: Kim, Kyung-Soo, et al.
Publicado: (2022)

Lobeglitazone, a Novel Thiazolidinedione, Improves Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Its Efficacy and Predictive Factors Related to Responsiveness
por: Lee, Yong-ho, et al.
Publicado: (2017)

Fatty Liver & Diabetes Statistics in Korea: Nationwide Data 2009 to 2017
por: Han, Eugene, et al.
Publicado: (2023)

Correlation of Albuminuria and Diabetic Retinopathy in Type-II Diabetes Mellitus Patients
por: Dash, Shovna, et al.
Publicado: (2022)

Sitagliptin improves albuminuria in patients with type 2 diabetes mellitus
por: Mori, Hiroko, et al.
Publicado: (2013)

Comparative Study on Adding Pioglitazone or Sitagliptin to Patients with Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin
por: Jameshorani, Maryam, et al.
Publicado: (2017)

The efficacy of pioglitazone for renal protection in diabetic kidney disease
por: Ho, Chao-Chung, et al.
Publicado: (2022)

Alogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus
por: Holland, Daniel Q, et al.
Publicado: (2014)

Effect of Pioglitazone on the Course of New-Onset Type 1 Diabetes Mellitus
por: Tafuri, Kimberly Sue, et al.
Publicado: (2013)

Differences in Factors Associated with Albuminuria according to Gender and Comorbidities of Hypertension and Diabetes
por: Jang, Miae, et al.
Publicado: (2015)

Lack of the effect of lobeglitazone, a peroxisome proliferator-activated receptor-γ agonist, on the pharmacokinetics and pharmacodynamics of warfarin
por: Jung, Jin Ah, et al.
Publicado: (2015)

Comparison of Vildagliptin and Pioglitazone in Korean Patients with Type 2 Diabetes Inadequately Controlled with Metformin
por: Kim, Jong Ho, et al.
Publicado: (2016)

A Novel User Utility Score for Diabetes Management Using Tailored Mobile Coaching: Secondary Analysis of a Randomized Controlled Trial
por: Lee, Min-Kyung, et al.
Publicado: (2021)

Safety and efficacy of low dose pioglitazone compared with standard dose pioglitazone in type 2 diabetes with chronic kidney disease: A randomized controlled trial
por: Satirapoj, Bancha, et al.
Publicado: (2018)

Prolonged Use of Carnitine-Orotate Complex (Godex(®)) Is Associated with Improved Mortality: A Nationwide Cohort Study
por: Park, Kye-Yeung, et al.
Publicado: (2022)

Trends in Prevalence of Hypertriglyceridemia and Related Factors in Korean Adults: A Serial Cross-Sectional Study
por: Park, Kye-Yeung, et al.
Publicado: (2023)

Lobeglitazone Exerts Anti-Inflammatory Effect in Lipopolysaccharide-Induced Bone-Marrow Derived Macrophages
por: Jeong, Dabin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6ivcduita60lnfvlemh2djnju4